Following the escalation of COVID-19 outbreak, Evonik’s contract manufacturer had shut-down its production facilities, as production and shipping of the amino acid ThreAMINO are affected
Dr Emmanuel Auer, head of animal nutrition business line at Evonik, explained, “We are facing a supply shortage for ThreAMINO. We have, therefore, decided to send a Force Majeure notification to our customers with immediate effect, in accordance with our contracts.”
“Meanwhile, we try the utmost to mitigate this situation and re-establish supply to our customers as fast as possible.”
Evonik is keeping its customers regularly informed as the situation develops.